<P>&nbsp;</P> <P align=justify><STRONG>Valneva is a brand new company in the <A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>biotechnology sector</A>, created from the merging of Vivalis and Austrian company Intercell on 28th May 2013</STRONG>. The company specialises in the <STRONG>development and commercialisation of vaccines and the discovery of antibodies</STRONG>, which it carries out internally but also in collaboration with industrial partners such as Sanofi, GSK, Merial, or Novartis. </P> <P align=justify><BR>The company has <STRONG>two sites in France, including the headquarters in Lyon, which houses a team of 18 employees in the <A title="" href="https://www.aderly.com/centre-recherche-et/biotechnology-cluster-lyon,p,21,EN.jsp" target=_blank>Techsud business park in Gerland</A></STRONG>. It also has a presence in Austria, Scotland, the United States, and Japan. Valneva has a total of 350 employees, of whom over 30% work in R&amp;D. </P> <P align=justify>&nbsp;</P> <P align=justify>The company&#8217;s primary objective is to achieve financial self-sufficiency in the medium term. After its shares were listed for trading on the NYSE Euronext Paris market, <STRONG>Valneva launched on 13th June 2013 a fully underwritten &#8364;40 million capital increase in order to support the development of its activities. <BR></STRONG></P>